Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/30276
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Coleções
- INI - Artigos de Periódicos [3394]
Metadata
Mostrar registro completo
CAN HERPES SIMPLEX VIRUS TYPE 2 SUPPRESSION SLOW HIV DISEASE PROGRESSION: A STUDY PROTOCOL FOR THE VALACYCLOVIR IN DELAYING ANTIRETROVIRAL TREATMENT ENTRY (VALIDATE) TRIAL
Antiviral Agents
Clinical Protocols
Disease Progression
HIV-1
Herpesvirus 2
Autor(es)
Afiliação
University Health Network. Toronto, Ontario, Canada.
University Health Network. Toronto, Ontario, Canada.
University Health Network. Toronto, Ontario, Canada.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundación Huesped. Buenos Aires, Argentina.
University Health Network. Toronto, Ontario, Canada.
University Health Network. Toronto, Ontario, Canada.
University Health Network. Toronto, Ontario, Canada.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundación Huesped. Buenos Aires, Argentina.
University Health Network. Toronto, Ontario, Canada.
Resumo em Inglês
Although highly active antiretroviral therapy (HAART) has dramatically decreased HIV-related morbidity and mortality, the associated costs, toxicities, and resistance risks make the potential delay of HAART initiation an attractive goal. Suppression of herpes simplex virus type 2 (HSV-2) may be a novel strategy for achieving this goal because HSV-2 is associated with clinically significant increases in HIV viral load, the primary driver of HIV disease progression.
Palavras-chave em inglês
AcyclovirAntiviral Agents
Clinical Protocols
Disease Progression
HIV-1
Herpesvirus 2
Compartilhar